Atherosclerosis is an inflammatory disease

Libby P (2007) Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 65:S140–146 Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695 Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802–815 Zernecke A, Shagdarsuren E, Weber C (2008) Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28:1897–1908 Brisset AC, Isakson BE, Kwak BR (2009) Connexins in vascular physiology and pathology. Antioxid Redox Signal 11:267–282 Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–519 Braunersreuther V, Mach F (2006) Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches? Cell Mol Life Sci 63:2079–2088 Mach F, Montecucco F, Steffens S (2008) Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 153:290–298 Hansson GK, Libby P, Schönbeck U et al (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91:281–291 Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291–1297 Masood A, Phillips B (2000) Sleep apnea. Curr Opin Pulm Med 6:479–484 Montecucco F, Burger F, Mach F et al (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294:H1145–H1155 Steffens S, Veillard NR, Arnaud C et al (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434:782–786 Montecucco F, Lenglet S, Braunersreuther V et al (2009) CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol . doi:10.1016/j.yjmcc.2008.12.014 Scheen AJ (2008) CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 20(Suppl 1):139–146 Van Gaal L, Pi-Sunyer X, Després JP et al (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31(Suppl 2):S229–S240 Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207